Scisparc Ltd.’s Mitocarex Bio Ltd. venture has validated the potential significant involvement of its target SLC25 carrier protein, using non-small-cell lung cancer (NSCLC) cells with diverse genetic backgrounds. Mitocarex used genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors, to demonstrate the discovery.
Researchers from Shandong University and affiliated organizations reported the discovery and preclinical characterization of novel 68Ga-labeled PSMA-targeting tracers for the diagnosis of prostate cancer.
The adaptation of cancer cells to therapies limits the effectiveness of treatments. However, understanding the mechanisms they use to do it could help reverse them or be used to design more powerful drugs. Scientists at New York University (NYU) have studied the transitions causing resistance and have observed how it develops through a gradual process they have called the “resistance continuum.”
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized oxoisoindolinyl substituted piperidinedione derivative molecular glue degraders characterized as IKZF1, IKZF3 and GSPT1 degradation inducers. They are reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders.
Jiangsu Vcare Pharmatech Co. Ltd. has created new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to estrogen receptor α (ER-α)-binding moiety through a linker. They are reported to be useful for the treatment of cancer and infections.
Acrivon Therapeutics Inc. has identified new pyrimidine carboxamide compounds acting as Wee1-like protein kinase (Wee1) inhibitors potentially useful for the treatment of cancer.
Zymeworks Inc. has received IND clearance from the FDA for ZW-191, the company’s novel folate receptor-α (FRα)-targeted topoisomerase I (TOPO1) inhibitor antibody-drug conjugate (ADC). Clinical development is set to begin this year, with filings to initiate studies outside the U.S. to be made in the second half of this year.
Researchers at Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM) and Université Côte d'Azur have divulged amidinourea derivatives reported to be useful for the treatment of cancer, in particular for BRAF inhibitor-resistant melanoma.
Acrivon Therapeutics Inc. has disclosed membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
RSS
